Access the full text.
Sign up today, get DeepDyve free for 14 days.
Jian Wu, Fenghua Zhang, F. Fang, Haiyan Chang, Fuyan Wang, Zhongdong Yang, Bo Sun, Ze Chen, Ze Chen (2010)
Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes.Vaccine, 28 15
Paula Traquina, M. Morandi, M. Contorni, G. Nest (1996)
MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates.The Journal of infectious diseases, 174 6
A. Banzhoff, P. Nacci, A. Podda (2003)
A New MF59-Adjuvanted Influenza Vaccine Enhances the Immune Response in the Elderly with Chronic Diseases: Results from an Immunogenicity Meta-AnalysisGerontology, 49
G. Giudice, A. Hilbert, R. Bugarini, A. Minutello, O. Popova, D. Toneatto, Ines Schoendorf, A. Borkowski, R. Rappuoli, A. Podda (2006)
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.Vaccine, 24 16
V. Baldo, T. Baldovin, A. Floreani, A. Carraro, R. Trivello (2007)
MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.Vaccine, 25 20
Liyun Zheng, Fuyan Wang, Zhongdong Yang, Jianjun Chen, Haiyan Chang, Ze Chen (2009)
A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in miceBMC Infectious Diseases, 9
Victor Huber, R. Mckeon, M. Brackin, L. Miller, Rachael Keating, Scott Brown, N. Makarova, D. Pérez, G. Macdonald, J. McCullers (2006)
Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against InfluenzaClinical and Vaccine Immunology, 13
J. Beigel, J. Farrar, A. Han, F. Hayden, R. Hyer, M. Jong, S. Lochindarat, Thi Nguyen, Tran Nguyen, T. Tran, A. Nicoll, S. Touch, K. Yuen (2005)
Avian influenza A (H5N1) infection in humans.The New England journal of medicine, 353 13
L. Muller, K. Gorter, E. Hak, W. Goudzwaard, F. Schellevis, A. Hoepelman, G. Rutten (2005)
Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 41 3
I. Stephenson, K. Nicholson, R. Glück, R. Mischler, R. Newman, A. Palache, N. Verlander, F. Warburton, J. Wood, M. Zambon (2003)
Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trialThe Lancet, 362
Meizhen Qiu, F. Fang, Yan Chen, Huálín Wáng, Quanjiao Chen, Haiyan Chang, Fuyan Wang, Hanzhong Wang, Ran Zhang, Ze Chen (2006)
Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.Biochemical and biophysical research communications, 343 4
F. Ansaldi, S. Bacilieri, P. Durando, L. Sticchi, L. Valle, E. Montomoli, G. Icardi, R. Gasparini, P. Crovari (2008)
Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.Vaccine, 26 12
C. Mclaren, M. Verbonitz, S. Daniel, G. Grubbs, F. Ennis (1977)
Effect of priming infection on serologic response to whole and subunit influenza virus vaccines in animals.The Journal of infectious diseases, 136 Suppl
R. Gasparini, T. Pozzi, E. Montomoli, E. Fragapane, F. Senatore, M. Minutello, A. Podda (2004)
Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjectsEuropean Journal of Epidemiology, 17
Z. Vajo, L. Kósa, Ildiko Visontay, Máté Jankovics, I. Jankovics (2007)
Inactivated Whole Virus Influenza A (H5N1) VaccineEmerging Infectious Diseases, 13
Arnt‐Ove Hovden, R. Cox, L. Haaheim (2005)
Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c miceScandinavian Journal of Immunology, 62
T. Chotpitayasunondh, K. Ungchusak, W. Hanshaoworakul, Supamit Chunsuthiwat, P. Sawanpanyalert, R. Kijphati, S. Lochindarat, P. Srisan, P. Suwan, Yutthasak Osotthanakorn, T. Anantasetagoon, Supornchai Kanjanawasri, Sureeporn Tanupattarachai, Jiranun Weerakul, Ruangsri Chaiwirattana, M. Maneerattanaporn, Rapol Poolsavatkitikool, K. Chokephaibulkit, A. Apisarnthanarak, S. Dowell (2005)
Human Disease from Influenza A (H5N1), Thailand, 2004Emerging Infectious Diseases, 11
Jiang-tao Lin, Jiansan Zhang, Xiao-Ping Dong, H. Fang, Jiang-ting Chen, N. Su, Q. Gao, Zhenshan Zhang, Yu-xuan Liu, Zhihong Wang, Meng Yang, Ruihua Sun, Changgui Li, Sue-Chen Lin, Mei Ji, Yan Liu, Xu Wang, J. Wood, Zijian Feng, Yu Wang, W. Yin (2006)
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 368
R. Burke, C. Goldbeck, P. Ng, L. Stanberry, G. Ott, G. Nest (1994)
The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine.The Journal of infectious diseases, 170 5
L. Bungener, F. Geeraedts, Wouter Veer, J. Medema, J. Wilschut, A. Huckriede (2008)
Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.Vaccine, 26 19
S. Geerlings, A. Hoepelman (1999)
Immune dysfunction in patients with diabetes mellitus (DM).FEMS immunology and medical microbiology, 26 3-4
S. Tamura, H. Asanuma, Yuji Ito, Y. Hirabayashi, Yujiro Suzuki, T. Nagamine, C. Aizawa, T. Kurata, A. Oya (1992)
Superior cross‐protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccineEuropean Journal of Immunology, 22
I. Leroux-Roels, Roger Bernhard, Pascal Gérard, M. Drame, Emmanuel Hanon, G. Leroux-Roels (2008)
Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza VaccinePLoS ONE, 3
Steven Smith, G. Poland (2004)
Influenza and pneumococcal immunization in diabetes.Diabetes care, 27 Suppl 1
P. Pozzilli, P. Arduini, N. Visalli, J. Sutherland, M. Pezzella, C. Galli, S. Corradini, L. Biasio, E. Gale, D. Andreani (1987)
Reduced protection against hepatitis B virus following vaccination in patients with Type 1 (insulin-dependent) diabetesDiabetologia, 30
M. Minutello, F. Senatore, G. Cecchinelli, M. Bianchi, T. Andréani, A. Podda, P. Crovari (1999)
Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons.Vaccine, 17 2
A. Ninomiya, M. Imai, M. Tashiro, T. Odagiri (2007)
Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.Vaccine, 25 18
G. Ott, G. Barchfeld, D. Chernoff, R. Radhakrishnan, P. Hoogevest, G. Nest (1995)
MF59. Design and evaluation of a safe and potent adjuvant for human vaccines.Pharmaceutical biotechnology, 6
K. Renegar, P. Small, L. Boykins, P. Wright (2004)
Role of IgA versus IgG in the Control of Influenza Viral Infection in the Murine Respiratory Tract1The Journal of Immunology, 173
J. Valensi, J. Carlson, G. Nest (1994)
Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.Journal of immunology, 153 9
D. Riel, V. Munster, E. Wit, G. Rimmelzwaan, R. Fouchier, A. Osterhaus, T. Kuiken (2006)
H5N1 Virus Attachment to Lower Respiratory TractScience, 312
J. Treanor, J. Campbell, K. Zangwill, T. Rowe, M. Wolff (2006)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.The New England journal of medicine, 354 13
D. Cataldo, G. Nest (1997)
The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice.Vaccine, 15 16
Steven Smith, G. Poland (2003)
Immunization and the prevention of influenza and pneumococcal disease in people with diabetes.Diabetes care, 26 Suppl 1
F. Geeraedts, L. Bungener, Judith Pool, Wouter Veer, J. Wilschut, A. Huckriede (2008)
Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCsInfluenza and Other Respiratory Viruses, 2
W. Beyer, A. Palache, A. Osterhaus (1998)
Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split VaccinesClinical Drug Investigation, 15
E. Szyszko, K. Brokstad, R. Cox, Arnt‐Ove Hovden, A. Madhun, L. Haaheim (2006)
Impact of Influenza Vaccine Formulation with a Detailed Analysis of the Cytokine ResponseScandinavian Journal of Immunology, 64
Uenza Manu (2002)
WHO Manual on Animal Influenza Diagnosis and Surveillance
Q. Zhu, Haiyan Chang, Yan Chen, F. Fang, Changyong Xue, Fenghua Zhang, Meizhen Qiu, Hanzhong Wang, Bin Wang, Ze Chen (2005)
Protection of inactivated influenza virus vaccine against lethal influenza virus infection in diabetic mice.Biochemical and biophysical research communications, 329 1
J. Bresson, C. Perronne, O. Launay, C. Gerdil, M. Saville, J. Wood, K. Höschler, M. Zambon (2006)
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 367
Quanjiao Chen, H. Kuang, Huadong Wang, F. Fang, Zhongdong Yang, Zhiping Zhang, Xian'en Zhang, Ze Chen (2009)
Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virusVirus Genes, 38
J. Treanor, Bethanie Wilkinson, Feda Masseoud, Jean Hu‐Primmer, Rosalyn Battaglia, D. O'Brien, M. Wolff, G. Rabinovich, W. Blackwelder, J. Katz (2001)
Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.Vaccine, 19 13-14
R. Diepersloot, K. Bouter, W. Beyer, J. Hoekstra, N. Masurel (1987)
Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitusDiabetologia, 30
K. Nicholson, D. Tyrrell, P. Harrison, C. Potter, R. Jennings, A. Clark, G. Schild, J. Wood, R. Yetts, V. Seagroatt, A. Huggins, S. Anderson (1979)
Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions.Journal of biological standardization, 7 2
P. Wright, J. Thompson, W. Vaughn, David Folland, S. Sell, D. Karzon (1977)
Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity.The Journal of infectious diseases, 136 Suppl
A. Wack, B. Baudner, A. Hilbert, I. Manini, S. Nuti, Simona Tavarini, Hanno Scheffczik, M. Ugozzoli, Manmohan Singh, J. Kazzaz, E. Montomoli, G. Giudice, R. Rappuoli, D. O’hagan (2008)
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.Vaccine, 26 4
W E Beyer, A M Palache, A D Osterhaus (1998)
Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: A review and meta-analysis of the literatureClin Drug Investig, 15
Vaccination is the preferred strategy for the prevention of influenza virus infection. Both H5N1 subunit and split vaccines have shown poor immunogenicity in clinical trials thus far. Therefore, it is urgent to develop more immunogenic and antigen-sparing H5N1 influenza vaccines as well as safe and effective adjuvants for humans, especially for immunocompromised people such as patients with diabetes mellitus. In this study, the protective effect of an MF59-adjuvanted inactivated whole-virion H5N1 vaccine was investigated in a type 1 diabetic mouse model. Mice (both healthy and diabetic) were immunized with a single dose of the inactivated vaccine, alone or adjuvanted with MF59 or Al(OH) 3 . After four weeks, mice were challenged with a lethal dose of H5N1 virus. Antibody responses, survival rates, lung virus titers and body weight changes were tested. The results showed that addition of MF59 or Al(OH) 3 to the vaccine enhanced the antibody responses in both healthy mice and diabetic mice, but the MF59-adjuvanted groups showed higher antibody responses than the Al(OH) 3 -adjuvanted groups. The addition of MF59 or Al(OH) 3 to the vaccine led to a conversion of the immune response from a Th1-biased response to an enhanced mixed Th1/Th2 profile. The MF59-adjuvanted inactivated whole-virion H5N1 vaccine provided superior protection in type 1 diabetic mice to either the vaccine alone or the vaccine adjuvanted with Al(OH) 3 .
Archives of Virology – Springer Journals
Published: Mar 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.